Abstract:As the most important intestinal mucosal barrier of the main body, the innate immune barrier in intestinal tract plays especially pivotal roles in the overall health conditions of infants and young children; therefore, how to strengthen the innate immune barrier is pivotal. A variety of bioactivities of lactoferrin (LF) has been widely proved, including alleviating enteritis and inhibiting colon cancer; however, the effects of LF on intestinal immune barrier in infants and young children are still unclear, and the specific mechanism on how LF inhibits infantile enteritis by regulating immune signaling pathways is unrevealed. In the present study, we firstly performed pharmacokinetic analyses of LF in mice intestinal tissues, stomach tissues and blood, through different administration methods, to confirm the metabolic method of LF in mammals. Then we constructed in Vitro and in Vivo infantile intestinal immune barrier damage models utilizing lipopolysaccharide (LPS), and evaluated the effects of LF in alleviating LPS-induced intestinal immune barrier damage. Next, the related immune molecular mechanism on how LF exerted protective effects was investigated, through RNA-seq analyses of the mouse primary intestinal epithelial cells, and the specific genes were analyzed and screened out. Finally, the genes and their related immune pathway were validated in mRNA and protein levels; the portions of special immune cells (CD4+ T cells and CD8+ T cells) were also detected to further support our experimental results. Pharmacokinetic analyses demonstrated that the integrity of LF could reach mice stomach and intestine after oral gavage within 12 h, and the proper administration of LF should be the oral route. LF was proven to down-regulate the expression levels of inflammatory cytokines in both the primary intestinal epithelial cells and mice blood, especially LF without iron (Apo-LF), indicating LF alleviated infantile intestinal immune barrier damage induced by LPS. And through RNA-seq analyses of the mouse primary intestinal epithelial cells treated with LPS and LF, embryonic lethal abnormal vision Drosophila 1 (ELAVL1) was selected as one of the key genes, then the ELAVL1/PI3K/NF-κB pathway regulated by LF was verified to participate in the protection of infantile intestinal immune barrier damage in our study. Additionally, the ratio of blood CD4+/CD8+ T cells was significantly higher in the LF-treated mice than in the control mice, indicating that LF distinctly reinforced the overall immunity of infantile mice, further validating the strengthening bioactivity of LF on infantile intestinal immune barrier. In summary, LF was proven to alleviate LPS-induced intestinal immune barrier damage in young mice through regulating ELAVL1-related immune signaling pathways, which would expand current knowledge of the functions of bioactive proteins in foods within different research layers, as well as benefit preclinical and clinical researches in a long run.

1 Protective Role of Bovine Lactoferrin on Intestinal 2 Epithelial Barrier In Vitro 3

The In Vitro Protective Role Of Bovine Lactoferrin On Intestinal Epithelial Barrier

Effects of lactoferrin on intestinal epithelial cell growth and differentiation: an in vivo and in vitro study

Lactoferrin Attenuates Lipopolysaccharide-Stimulated Inflammatory Responses and Barrier Impairment Through the Modulation of NF-κB/MAPK/Nrf2 Pathways in IPEC-J2 Cells.

Enteral supplementation of bovine lactoferrin improves gut barrier function in rats after massive bowel resection.

Porcine Lactoferrin-Derived Peptide LFP-20 Protects Intestinal Barrier by Maintaining Tight Junction Complex and Modulating Inflammatory Response.

Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk

Physico-chemical properties influence the functions and efficacy of commercial bovine lactoferrins

Oral Administration of Bovine Lactoferrin-Derived Lactoferricin (lfcin) B Could Attenuate Enterohemorrhagic Escherichia Coli O157:H7 Induced Intestinal Disease Through Improving Intestinal Barrier Function and Microbiota

Antibacterial, anti-invasive, and anti-inflammatory activity of bovine lactoferrin extracted from milk or colostrum versus whole colostrum

Lactoferrin Alleviates Lipopolysaccharide-Induced Infantile Intestinal Immune Barrier Damage by Regulating an ELAVL1-Related Signaling Pathway

The Protective Effects of Lactoferrin on Aflatoxin M1-Induced Compromised Intestinal Integrity

Dietary Bovine Lactoferrin Reduces the Deleterious Effects of Lipopolysaccharide Injection on Mice Intestine

Oral administration of LfcinB alleviates DSS-induced colitis by improving the intestinal barrier and microbiota

Bovine Lactoferricin Ameliorates Intestinal Inflammation and Mucosal Barrier Lesions in Colitis Through NF-κB/NLRP3 Signaling Pathways

Temporal Dynamics of T Helper Populations in the Proximal Small Intestine after Oral Bovine Lactoferrin Administration in BALB/c Mice

Bovine Lactoferrin Pre-Treatment Induces Intracellular Killing of AIEC LF82 and Reduces Bacteria-Induced DNA Damage in Differentiated Human Enterocytes

Effect of Bovine Lactoferrin and Human Lactoferrin on the Proliferative Activity of the Osteoblast Cell Line MC3T3-E1 in Vitro.

Effects of dietary supplementation of bovine lactoferrin on growth performance, immune function and intestinal health in weaning piglets

Lactoferrin from Bovine Milk: A Protective Companion for Life

Secretions of Bifidobacterium infantis and Lactobacillus acidophilus Protect Intestinal Epithelial Barrier Function.